CORDIS
EU research results

CORDIS

English EN

Non-biased fluorescent dyes as markers of drugs for optical in cellulo and in vivo imaging

Objective

Imaging of distribution of drugs in mice delivers accurate information for confirmation that the mechanism of action elaborated in cell-based assays is also operative in vivo. These data are critical for the transfer of drug discovery process from pre-clinical to clinical phase. To enable the imaging, drugs should be labeled with easily detectable moieties, e.g. radioactive markers and fluorescent dyes. Ideally, the markers should not affect in vivo properties of the drugs that can be better achieved with radioactive markers, since they can be selected to be small: e.g. a single atom marker 18F applied in positron emission tomography. Despite this intrinsic advantage, PET suffers from safety issues, since radioactivity is harmful to humans and environment. In terms of safety optical imaging is much better and, therefore, in future can replace PET. However, fluorescent dyes compatible with the optical imaging are usually extended pi-systems carrying overall positive or negative charge. Their conjugation strongly affects properties of the majority of medium sized and low molecular weight drugs that limits the applicability of this method in drug discovery. The interdisciplinary and intersectoral consortium NoBiasFluors consisting of 4 academic and 2 industrial teams aims at achieving a breakthrough solution of this problem. We will develop non-biased red and near infrared fluorescent dyes, which are compatible with in vivo optical imaging and do not affect properties of drugs upon their conjugation. This goal will be achieved by the careful optimization of dye structure, polarity and charge. We will confirm the functionality of the developed dyes for labeling of representative drugs (anticancer N-alkylaminoferrocene-based prodrugs, D-peptides targeting Alzheimer’s disease) and binders of biomolecules (nucleopeptides and lectins) and monitoring their distribution both in cellulo and in vivo (for a selected labeled drug).
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN NUERNBERG

Address

Schlossplatz 4
91054 Erlangen

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 133 400

Participants (4)

Sort alphabetically

Sort by EU Contribution

Expand all

CONSIGLIO NAZIONALE DELLE RICERCHE

Italy

EU Contribution

€ 92 000

INSTITUTUL DE CHIMIE MACROMOLECULARA PETRU PONI

Romania

EU Contribution

€ 142 600

LIMITED LIABILITY SCIENTIFIC SERVICE COMPANY OTAVA

Ukraine

EU Contribution

€ 230 000

NAUKOVO VYROBNICHYJ KOOPERATYV LECTINOTEST

Ukraine

EU Contribution

€ 73 600

Partners (1)

Sort alphabetically

Expand all

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

United States

Project information

Grant agreement ID: 872331

Status

Grant agreement signed

  • Start date

    1 January 2020

  • End date

    31 December 2023

Funded under:

H2020-EU.1.3.3.

  • Overall budget:

    € 699 200

  • EU contribution

    € 671 600

Coordinated by:

FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN NUERNBERG

Germany